CHINOOK THERAPEUTICS, INC.
DelistedCIK 1435049fmd_1PPKH9TQ7PBY61NZ9JKQKWS7J2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2023, 39 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 13 | 73 | 51 | 17 | 15 | 17 | 1 | 52 | 6 |
| Realized investment gains (losses) | – | – | – | – | – | – | 0 | – | – | – |
| Research and development | 11 | 24 | 59 | 88 | 89 | 76 | 17 | 36 | 97 | 141 |
| Total operating expenses | 15 | 33 | 87 | 123 | 124 | 116 | 20 | 57 | – | – |
| Operating income | (15) | (19) | (14) | (72) | (106) | (101) | (20) | (56) | (99) | (185) |
| Interest expense | 1 | 2 | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | 0 | 2 | 3 | 5 | 5 | – | – | – |
| Other non-operating income (expense) | 0 | 2 | (0) | (0) | (0) | (0) | 0 | 0 | (0) | – |
| Income before taxes | (16) | (17) | (39) | (70) | (103) | (96) | (47) | (84) | (101) | (184) |
| Income tax expense | – | – | (0) | 21 | (11) | (1) | (0) | (2) | 2 | 4 |
| Net income from continuing operations | – | – | (39) | (91) | (92) | (95) | (46) | (82) | (103) | (188) |
| Net income | (16) | (17) | (39) | (91) | (92) | (95) | (47) | (82) | (103) | (188) |